Dr. Phillipp Lang, who will leave ConforMIS as CEO when a replacement is named, believes robotics in total knee replacements is a marketing gimmick.

Arundhati Parmar

ConforMIS iTotal PS Custom Knee Launched In March

Many believe that robot-assisted surgery will transform how surgery is done and it will be a boon for both patients and surgeons.

One person who begs to differ is Philipp Lang, CEO of orthopedics...

May 16th, 2016
0

What is behind the public's wariness of the 21st Century Cures Act?

Jim Dickinson

As many in industry look forward hopefully to the enactment of the bipartisan 21st Century Cures Act with its promise of faster, easier FDA healthcare product approvals and clearances, a new public opinion poll from Harvard T.H. Chan School of Public Health and Stat finds a majority of Americans distrust it.

The legislation passed the House comfortably over a year ago, and the Senate’s Health, Education, Labor and Pensions Committee passed five separate bills in April that constitute its version of 21st Century...

May 16th, 2016
0

A Frost and Sullivan analyst speculates on what Boston Scientific should do given that two of its main competitors have engaged in megamergers.  

Arundhati Parmar

 

Medtronic has bought Covidien, St. Jude Medical has given itself to Abbott Laboratories. So two of Boston Scientific's biggest competitors have chosen scale as an answer to answer the challenges of today's healthcare industry.

What should the Massachusetts company do, if anything to stay relevant in an evolving marketplace? MD+DI reached out to Venkat Rajan, industry manager for medical devices and global director of research, Visionary Healthcare at Frost & Sullivan for some answers.

...
May 16th, 2016
0

All of us love a good David vs. Goliath story, but in business it's not easy to see them happening with much regularity.

Arundhati Parmar

Take the example of Research Triangle, N.C.-based TransEnterix. The public company was riding high expecting FDA to greenlight its SurgiBot robotic system. CEO Todd Pope was fuly expecting that SurgiBot's clearance would increase the small footprint of surgical robots in the U.S. created by Intuitive Surgical's pioneering but expensive Da Vinci robots. On April 20,...

May 13th, 2016
0

BD's Commentary on M&A

"As many of you already know, in March, we celebrated the one-year anniversary of the closing of CareFusion, and we are extremely proud of our achievements over the past year. We have been acutely focused on the integration and a significant amount of work driven by the integration teams across the businesses . . .

In the short run, we still have the flexibility to do plug-in acquisitions."

Vincent Forlenza, BD chairman, president, and CEO...

May 13th, 2016
0

Hologic's Commentary on M&A

"Yes we are ready and willing to spend there on M&A and actually we did make an acquisition of our own stock in the quarter. That was actually a pretty good acquisition that we made and we are feeling pretty good about that.

The teams are definitely looking and where Bob and Eric and I are now reviewing on a more regular basis ideas . . . Ultimately I look forward to the day that we have no converts left on the balance sheet, but I would suspect we will be doing some acquisitions along the way while we continue to clean those up....

May 13th, 2016
0

Smith & Nephew's Commentary on M&A

"Our entry into the fast-growing area of orthopedic robotic-assisted surgery with the acquisition of Blue Belt is off to a good start. The integration has been smooth. And we’re excited about the prospects and our pipeline . . .

So the mid-tier was really one of a number of interests that we have in M&A. As you know M&A remains one of our five key strategic pillars. There’s no change really in the level of interest. Clearly, there are a number of areas that we’re focused on in terms of high growth areas in...

May 13th, 2016
0

Stryker's Commentary on M&A

"We still have significant capacity to do extra deals. So we had a one-notch downgrade from both S&P and Moody's and if you look at S&P, we went from an A plus to A rating. We're committed to maintaining investment grade, but there's obviously a large gap between A rating and the low end of investment grade. Keep in mind that the vast majority of the deals we do are small tuck-in deals. That will continue to be the case for Stryker. That is where we drive the most value and we find great technologies that we can give to our fabulous sales forces to drive.

...

May 13th, 2016
0

Boston Scientific's Commentary on M&A

"Near term, our capital allocation priorities are to prepay debt, manage our contingencies, and pursue tuck-in M&A."

Daniel Brennan, Boston Scientific CFO, according to a Seeking Alpha transcript of the company's first quarter earnings call

...
May 13th, 2016
0

2016 has already been a busy year for mergers and acquisitions. Will the robust M&A activity in the medtech industry continue?

M&A in recent years has dramatically transformed the medtech industry, and executives have continued to sign deals, with several transactions worth hundreds of millions and the Abbott-St. Jude Medical megamerger already announced this year.

Will medtech keep up this brisk purchasing pace? Do fewer potential targets mean fewer future deals? With large medical device companies snapping up other companies, will the need for integration and time to digest those acquisitions delay or prevent other transactions?

Read on for more recent commentary from...

May 13th, 2016
0